Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Gentium SpA (GENTY)

OTC Markets
Currency in USD
Disclaimer
56.10
0.00(0.00%)
Closed
GENTY Scorecard
Fair Value
Unlock Value
Day's Range
56.1056.10
52 wk Range
0.0056.10
Prev. Close
56.1
Open
56.1
Day's Range
56.1-56.1
52 wk Range
0-0
Volume
0
Average Vol. (3m)
21,560
1-Year Change
0%
Shares Outstanding
17,741,189
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about GENTY?
Vote to see community's results!
or

Gentium SpA Company Profile

Gentium S.p.A., a biopharmaceutical company, is engaged in the research and development of drugs derived from DNA and DNA molecules. It develops and manufactures defibrotide, an investigational active pharmaceutical ingredient (API) drug based on a mixture of single-and double-stranded DNA extracted from swine intestinal mucosa for the treatment and prevention of hepatic veno-occlusive disease (VOD), a life-threatening complication of hematopoietic stem cell transplantation. The company has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also provides other APIs consisting of sodium heparin; Urokinase, which is made from human urine; and sulglicotide that is developed from swine duodenum. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy. Gentium S.p.A operates as a subsidiary of Jazz Pharmaceuticals plc.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.